Psyence Biomedical (PBM) announced that it has received notice from the Nasdaq Hearings panel that the Company has regained compliance with all applicable Nasdaq continued listing requirements. As previously announced, Psyence Biomed requested to be transferred from The Nasdaq Global Market to The Nasdaq Capital Market, effective November 15, 2024. As a result of this transfer, the Company regained compliance with listing rules 5550(a)(5), the $1.0 million minimum market value of publicly held shares requirement, and 5550(b)(1), the $2.5 million minimum stockholders’ equity requirement.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PBM:
- Psyence Biomedical files to sell 10.9M shares of common stock for holders
- Psyence Biomedical Signs Exclusive Licensing Agreement with Optimi Health
- Psyence Biomedical Advances in Phase IIb Psilocybin Clinical Trial
- Psyence Biomedical highlights progress on Phase IIb clinical trial
- Rising High: Organigram acquires Motif Labs for C$90M upfront